PriceTargets.com logo

NASDAQ:ZNTL - Zentalis Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $69.83
  • Forecasted Upside: -0.64 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$70.28 As of 09/17/2021 01:00 AM ET
▼ -2.56 (-3.51%)

This chart shows the closing price for ZNTL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Zentalis Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZNTL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZNTL

Analyst Price Target is $69.83
▼ -0.64% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Zentalis Pharmaceuticals in the last 3 months. The average price target is $69.83, with a high forecast of $91.00 and a low forecast of $44.00. The average price target represents a -0.64% upside from the last price of $70.28.

This chart shows the closing price for ZNTL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 investment analysts is to buy stock in Zentalis Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/20/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/20/2021UBS GroupInitiated CoverageBuy$91.00Low
5/19/2021HC WainwrightBoost Price TargetPositive ➝ Buy$65.00 ➝ $80.00Medium
4/19/2021SVB LeerinkBoost Price TargetOutperform$60.00 ➝ $64.00N/A
4/12/2021SVB LeerinkBoost Price TargetOutperform$44.00 ➝ $60.00High
3/26/2021HC WainwrightBoost Price TargetBuy$43.00 ➝ $65.00High
1/19/2021WedbushInitiated CoverageOutperform$65.00High
12/16/2020Morgan StanleyBoost Price TargetOverweight$50.00 ➝ $75.00High
11/11/2020Morgan StanleyBoost Price TargetOverweight$49.00 ➝ $50.00High
9/28/2020Cantor FitzgeraldInitiated CoverageOverweight$44.00High
8/27/2020HC WainwrightInitiated CoverageBuy$43.00High
8/24/2020Morgan StanleyBoost Price TargetOverweight$45.00 ➝ $49.00Low
7/28/2020SVB LeerinkReiterated RatingBuyHigh
5/12/2020Morgan StanleyReiterated RatingOverweight$45.00High
4/28/2020Morgan StanleyInitiated CoverageOverweight$45.00High
4/28/2020SVB LeerinkInitiated CoverageOutperform$45.00High
4/28/2020GuggenheimInitiated CoverageBuy$45.00High
4/28/2020Jefferies Financial GroupInitiated CoverageBuy$41.00High
(Data available from 9/20/2016 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/22/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/22/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2021
  • 1 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2021

Current Sentiment

  • 1 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Zentalis Pharmaceuticals logo
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidates are the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer; and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, as well as in Phase 1b clinical trial in combination with chemotherapy in patients with advanced ovarian cancer. The company also develops ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Read More

Today's Range

Now: $70.28
Low: $70.01
High: $73.60

50 Day Range

MA: $57.69
Low: $46.84
High: $73.50

52 Week Range

Now: $70.28
Low: $26.70
High: $74.99

Volume

1,767,300 shs

Average Volume

294,329 shs

Market Capitalization

$3.17 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.87

Frequently Asked Questions

What sell-side analysts currently cover shares of Zentalis Pharmaceuticals?

The following Wall Street research analysts have issued reports on Zentalis Pharmaceuticals in the last year: Cantor Fitzgerald, HC Wainwright, Morgan Stanley, SVB Leerink LLC, UBS Group AG, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for ZNTL.

What is the current price target for Zentalis Pharmaceuticals?

6 Wall Street analysts have set twelve-month price targets for Zentalis Pharmaceuticals in the last year. Their average twelve-month price target is $69.83, suggesting a possible downside of 0.6%. UBS Group AG has the highest price target set, predicting ZNTL will reach $91.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $44.00 for Zentalis Pharmaceuticals in the next year.
View the latest price targets for ZNTL.

What is the current consensus analyst rating for Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ZNTL will outperform the market and that investors should add to their positions of Zentalis Pharmaceuticals.
View the latest ratings for ZNTL.

What other companies compete with Zentalis Pharmaceuticals?

Other companies that are similar to Zentalis Pharmaceuticals include Zai Lab, Maravai LifeSciences, Ono Pharmaceutical, Dr. Reddy's Laboratories, Grifols, CureVac, Teva Pharmaceutical Industries, Bausch Health Companies, Ascendis Pharma A/S, United Therapeutics, Biohaven Pharmaceutical, Mirati Therapeutics, Evotec, Jazz Pharmaceuticals and BridgeBio Pharma.

How do I contact Zentalis Pharmaceuticals' investor relations team?

Zentalis Pharmaceuticals' physical mailing address is 530 SEVENTH AVENUE SUITE 2201, NEW YORK NY, 10018. The official website for Zentalis Pharmaceuticals is www.zentalis.com.